Skip to main content
Dilipkumar Reddy Kandula on Muck Rack

Dilipkumar Reddy Kandula

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dilipkumar Reddy

Contact Dilipkumar Reddy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SuFEx-based antitubercular compound irreversibly inhibits Pks13 - Nature

|
By Inna V. Krieger, Curtis A. Engelhart, Dongdong Liu, Bo Qin, Helena I. Boshoff, Dirk Schnappinger, Gregory Robertson, Peter Schultz, Sean Joseph, K. Barry Sharpless, Arnab Chatterjee, James C Sacchettini, Daniel Selle, Brendan Tsuda, Dilipkumar Reddy Kandula
| Nature Verified
Abstract Mycobacterium tuberculosis (Mtb) remains the world’s deadliest bacterial pathogen1. There is an urgent medical need to develop new drugs that shorten the treatment duration to combat widespread multi-drug-resistant and extensive-drug-resistant Mtb. Here, we present a preclinical covalent compound, CMX410, that contains an aryl fluorosulfate (SuFEx)2 warhead and uniquely targets the acyltransferase domain of Pks13, an essential enzyme in cell-wall biosynthesis.
Open in Who Shared Issue with article?
See all 1 articles